Abstract
Patients with multiple sclerosis (MS) often suffer from cognitive dysfunction; the underlying mechanisms have not been fully elucidated. Recent studies suggest that MS leads to heightened synaptic transmission and plasticity in different brain areas, and therefore may contribute to the observed behavioral abnormalities. Recent findings demonstrate synaptic plasticity changes in MS, including evidence from animal models of experimental autoimmune encephalomyelitis and human MS patients.
Keywords: Experimental autoimmune encephalomyelitis, inflammation, multiple sclerosis, N-methyl-D-aspartic acid, synaptic plasticity, trophic factor.
CNS & Neurological Disorders - Drug Targets
Title:Commentary (Changes of Synaptic Plasticity in Multiple Sclerosis)
Volume: 14 Issue: 2
Author(s): Ti-Fei Yuan, Chunlei Shan and Oscar Arias-Carrion
Affiliation:
Keywords: Experimental autoimmune encephalomyelitis, inflammation, multiple sclerosis, N-methyl-D-aspartic acid, synaptic plasticity, trophic factor.
Abstract: Patients with multiple sclerosis (MS) often suffer from cognitive dysfunction; the underlying mechanisms have not been fully elucidated. Recent studies suggest that MS leads to heightened synaptic transmission and plasticity in different brain areas, and therefore may contribute to the observed behavioral abnormalities. Recent findings demonstrate synaptic plasticity changes in MS, including evidence from animal models of experimental autoimmune encephalomyelitis and human MS patients.
Export Options
About this article
Cite this article as:
Yuan Ti-Fei, Shan Chunlei and Arias-Carrion Oscar, Commentary (Changes of Synaptic Plasticity in Multiple Sclerosis), CNS & Neurological Disorders - Drug Targets 2015; 14 (2) . https://dx.doi.org/10.2174/1871527313666141114203620
DOI https://dx.doi.org/10.2174/1871527313666141114203620 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Functional Interactions Between B Lymphocytes and the Innate Immune System
Infectious Disorders - Drug Targets LPS-induced Murine Neuroinflammation Model: Main Features and Suitability for Pre-clinical Assessment of Nutraceuticals
Current Neuropharmacology Micro- and Nano-particulate Strategies for Antigen Specific Immune Tolerance to Treat Autoimmune Diseases
Pharmaceutical Nanotechnology Telomere Length Variations in Aging and Age-Related Diseases
Current Aging Science The PD-1/PD-L1 Pathway in Human Pathology
Current Molecular Medicine Promotion of Remyelination by Immunoglobulins: Implications for the Treatment of Multiple Sclerosis
Current Pharmaceutical Design Purine Ionotropic (P2X) Receptors
Current Pharmaceutical Design Monoclonal Antibodies in the Treatment of Multiple Sclerosis
Current Medicinal Chemistry Renin-Angiotensin System in Central Nervous System Diseases and its Interaction with COVID-19
Current Medicinal Chemistry Pro-Inflammatory Cytokines: New Potential Therapeutic Targets for Obesity-Related Bone Disorders
Current Drug Targets Tyrphostins as Potential Therapeutic Agents for Acute Kidney Injury
Current Medicinal Chemistry “Metabolic Aspects” In Inflammatory Bowel Diseases
Current Drug Delivery Potential Role of TRAIL in the Management of Autoimmune Diabetes Mellitus
Current Pharmaceutical Design Purinergic Signalling: What is Missing and Needed Next? The Use of Transgenic Mice, Crystallographic Analysis and MicroRNA
CNS & Neurological Disorders - Drug Targets Targeting Regulatory T Cells in the Treatment of Type 1 Diabetes Mellitus
Current Molecular Medicine Lysosomal Storage Diseases and the Blood-Brain Barrier
Current Pharmaceutical Design IL-27: Friend or Foe in the Autoimmune Diseases
Current Immunology Reviews (Discontinued) The Role of Platelets and their Microparticles in Rehabilitation of Ischemic Brain Tissue
CNS & Neurological Disorders - Drug Targets Dysregulation of Neurotrophic and Haematopoietic Growth Factors in Alzheimer’s Disease: From Pathophysiology to Novel Treatment Strategies
Current Alzheimer Research An Overview of Notch Signaling in Adult Tissue Renewal and Maintenance
Current Alzheimer Research